Suppr超能文献

在控制家族性错误率的同时,进行个性化医疗中定性相互作用的变量选择。

Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate.

作者信息

Gunter Lacey, Zhu Ji, Murphy Susan

机构信息

Gunter Statistical Consulting, Provo, Utah 84604, USA.

出版信息

J Biopharm Stat. 2011 Nov;21(6):1063-78. doi: 10.1080/10543406.2011.608052.

Abstract

For many years, subset analysis has been a popular topic for the biostatistics and clinical trials literature. In more recent years, the discussion has focused on finding subsets of genomes which play a role in the effect of treatment, often referred to as stratified or personalized medicine. Though highly sought after, methods for detecting subsets with altering treatment effects are limited and lacking in power. In this article we discuss variable selection for qualitative interactions with the aim to discover these critical patient subsets. We propose a new technique designed specifically to find these interaction variables among a large set of variables while still controlling for the number of false discoveries. We compare this new method against standard qualitative interaction tests using simulations and give an example of its use on data from a randomized controlled trial for the treatment of depression.

摘要

多年来,亚组分析一直是生物统计学和临床试验文献中一个热门的话题。近年来,讨论的焦点集中在寻找基因组的亚组,这些亚组在治疗效果中发挥作用,通常被称为分层医学或个性化医学。尽管备受追捧,但检测具有改变治疗效果的亚组的方法有限且效力不足。在本文中,我们讨论定性交互作用的变量选择,旨在发现这些关键的患者亚组。我们提出了一种专门设计的新技术,用于在大量变量中找到这些交互作用变量,同时仍能控制错误发现的数量。我们使用模拟将这种新方法与标准的定性交互作用测试进行比较,并给出其在一项治疗抑郁症的随机对照试验数据中的应用示例。

相似文献

2
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.
J Natl Cancer Inst. 2010 Dec 1;102(23):1756-9. doi: 10.1093/jnci/djq427. Epub 2010 Nov 1.
4
LIBERTI: A SMART study in plastic surgery.
Clin Trials. 2018 Jun;15(3):286-293. doi: 10.1177/1740774518762435. Epub 2018 Mar 25.
6
Detecting treatment-covariate interactions using permutation methods.
Stat Med. 2015 May 30;34(12):2035-47. doi: 10.1002/sim.6457. Epub 2015 Mar 2.
7
Introduction: Personalized medicine: what is it and what are the challenges?
Fertil Steril. 2018 Jun;109(6):944-945. doi: 10.1016/j.fertnstert.2018.04.027.
8
Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
Stat Med. 2016 Apr 15;35(8):1245-56. doi: 10.1002/sim.6783. Epub 2015 Oct 28.
9
Personalized medicine in Europe: not yet personal enough?
BMC Health Serv Res. 2017 Apr 19;17(1):289. doi: 10.1186/s12913-017-2205-4.
10
Controlling the family-wise error rate in multi-arm, multi-stage trials.
Clin Trials. 2017 Jun;14(3):237-245. doi: 10.1177/1740774517694130. Epub 2017 Mar 19.

引用本文的文献

1
Simultaneous Feature Selection for Optimal Dynamic Treatment Regimens.
Stat Med. 2025 Jul;44(15-17):e70169. doi: 10.1002/sim.70169.
2
Nonparametric Biomarker Based Treatment Selection With Reproducibility Data.
Stat Med. 2024 Nov 30;43(27):5077-5087. doi: 10.1002/sim.10218. Epub 2024 Sep 18.
3
Statistical inference on qualitative differences in the magnitude of an effect.
Stat Med. 2024 Mar 30;43(7):1419-1440. doi: 10.1002/sim.10025. Epub 2024 Feb 2.
4
Ranking tailoring variables for constructing individualized treatment rules: an application to schizophrenia.
J R Stat Soc Ser C Appl Stat. 2022 Mar;71(2):309-330. doi: 10.1111/rssc.12533. Epub 2022 Mar 20.
5
A single-index model with a surface-link for optimizing individualized dose rules.
J Comput Graph Stat. 2022;31(2):553-562. doi: 10.1080/10618600.2021.1923521. Epub 2021 Jun 21.
6
Personalized optimal nutrition lifestyle for self obesity management using metaalgorithms.
Sci Rep. 2022 Jul 20;12(1):12387. doi: 10.1038/s41598-022-16260-w.
7
Evaluating the Effectiveness of Personalized Medicine With Software.
Front Big Data. 2021 May 18;4:572532. doi: 10.3389/fdata.2021.572532. eCollection 2021.
8
Predictive approaches to heterogeneous treatment effects: a scoping review.
BMC Med Res Methodol. 2020 Oct 23;20(1):264. doi: 10.1186/s12874-020-01145-1.
9
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.
Ann Intern Med. 2020 Jan 7;172(1):W1-W25. doi: 10.7326/M18-3668. Epub 2019 Nov 12.
10
Development and evaluating multimarker models for guiding treatment decisions.
BMC Med Inform Decis Mak. 2018 Jun 28;18(1):52. doi: 10.1186/s12911-018-0619-5.

本文引用的文献

1
The challenge of subgroup analyses--reporting without distorting.
N Engl J Med. 2006 Apr 20;354(16):1667-9. doi: 10.1056/NEJMp068070.
2
Maintenance treatment of major depression in old age.
N Engl J Med. 2006 Mar 16;354(11):1130-8. doi: 10.1056/NEJMoa052619.
3
Pharmacogenetics/genomics and personalized medicine.
Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R207-14. doi: 10.1093/hmg/ddi261.
5
An experimental design for the development of adaptive treatment strategies.
Stat Med. 2005 May 30;24(10):1455-81. doi: 10.1002/sim.2022.
6
Moving towards individualized medicine with pharmacogenomics.
Nature. 2004 May 27;429(6990):464-8. doi: 10.1038/nature02626.
9
Tests against qualitative interaction: exact critical values and robust tests.
Biometrics. 2001 Dec;57(4):1157-65. doi: 10.1111/j.0006-341x.2001.01157.x.
10
Naltrexone in the treatment of alcohol dependence.
N Engl J Med. 2001 Dec 13;345(24):1734-9. doi: 10.1056/NEJMoa011127.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验